Sara Bremer1, Nils T Vethe2, Morten Skauby3, Margrete Kasbo1,4, Elisabet D Johansson1,4, Karsten Midtvedt3, Stein Bergan2,4. 1. Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway. 2. Deptartment of Pharmacology, Oslo University Hospital, Oslo, Norway. 3. Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway. 4. Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway.
Abstract
AIMS: Despite pharmacokinetic monitoring of calcineurin inhibitors, the long-term outcome after transplantation (Tx) is still hampered by the side effects of these drugs. The aim of the present study was to characterize nuclear factor of activated T cells (NFAT)-regulated gene expression as a potential pharmacodynamic biomarker for further individualization of tacrolimus (Tac) therapy. METHODS: In 29 renal allograft recipients, samples were drawn once pre-Tx, and before and 1.5 h after Tac dosing at approximately 1 week, 6 weeks and 1 year post-Tx. Tac concentrations were measured by immunoassay, while the expression of genes encoding NFAT-regulated cytokines [interleukin 2 (IL2), interferon gamma (IFNG), colony stimulating factor 2 (CSF2)] and cytochrome P450 3A5 (CYP3A5) genotyping were determined by real-time polymerase chain reaction. RESULTS: The cytokine response after Tac dosing varied up to 46-fold between patients and changed significantly with time post-engraftment. Tac concentrations 1.5 h postdose (C1.5 ) >15 μg l-1 were associated with strong cytokine inhibition and residual gene expression (RGE) ≤10%, while lower Tac C1.5 resulted in more variable responses (RGE 2.5-68.7%). Patients with ongoing subclinical acute rejection (n = 5) demonstrated limited cytokine inhibition (RGE 39.7-72.6%), while patients with polyoma virus viraemia (n = 3) had relatively strong inhibition of cytokines (RGE 2.5-32.5%). By contrast, there was no association between Tac exposure and rejection or viraemia. CONCLUSIONS: The findings of our study support the potential of NFAT-regulated gene expression measurements as a pharmacodynamic tool for additional monitoring of Tac therapy, especially in the context of overimmunosuppression and viraemia.
AIMS: Despite pharmacokinetic monitoring of calcineurin inhibitors, the long-term outcome after transplantation (Tx) is still hampered by the side effects of these drugs. The aim of the present study was to characterize nuclear factor of activated T cells (NFAT)-regulated gene expression as a potential pharmacodynamic biomarker for further individualization of tacrolimus (Tac) therapy. METHODS: In 29 renal allograft recipients, samples were drawn once pre-Tx, and before and 1.5 h after Tac dosing at approximately 1 week, 6 weeks and 1 year post-Tx. Tac concentrations were measured by immunoassay, while the expression of genes encoding NFAT-regulated cytokines [interleukin 2 (IL2), interferon gamma (IFNG), colony stimulating factor 2 (CSF2)] and cytochrome P450 3A5 (CYP3A5) genotyping were determined by real-time polymerase chain reaction. RESULTS: The cytokine response after Tac dosing varied up to 46-fold between patients and changed significantly with time post-engraftment. Tac concentrations 1.5 h postdose (C1.5 ) >15 μg l-1 were associated with strong cytokine inhibition and residual gene expression (RGE) ≤10%, while lower Tac C1.5 resulted in more variable responses (RGE 2.5-68.7%). Patients with ongoing subclinical acute rejection (n = 5) demonstrated limited cytokine inhibition (RGE 39.7-72.6%), while patients with polyoma virus viraemia (n = 3) had relatively strong inhibition of cytokines (RGE 2.5-32.5%). By contrast, there was no association between Tac exposure and rejection or viraemia. CONCLUSIONS: The findings of our study support the potential of NFAT-regulated gene expression measurements as a pharmacodynamic tool for additional monitoring of Tac therapy, especially in the context of overimmunosuppression and viraemia.
Authors: Thomas Giese; Martin Zeier; Peter Schemmer; Waldemar Uhl; Margarita Schoels; Thomas Dengler; Markus Buechler; Stefan Meuer Journal: Transplantation Date: 2004-02-15 Impact factor: 4.939
Authors: Matthias Büchler; Steve Chadban; Edward Cole; Karsten Midtvedt; Eric Thervet; Hans Prestele; Paul Keown Journal: Nephrol Dial Transplant Date: 2005-10-04 Impact factor: 5.992
Authors: L Cherkassky; M Lanning; P N Lalli; J Czerr; H Siegel; L Danziger-Isakov; T Srinivas; A Valujskikh; D A Shoskes; W Baldwin; R L Fairchild; E D Poggio Journal: Am J Transplant Date: 2011-05-12 Impact factor: 8.086
Authors: Claudia Sommerer; Wolfgang Hartschuh; Alexander Enk; Stefan Meuer; Martin Zeier; Thomas Giese Journal: Clin Transplant Date: 2008-04-03 Impact factor: 2.863
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Yang Shumei; Li Yi; Meng Huanyu; Li Zhibin; Jin Wanlin; Xu Liqun; Yang Huan Journal: Eur J Clin Pharmacol Date: 2019-02-07 Impact factor: 2.953
Authors: Amelia R Cossart; Nicole M Isbel; Carla Scuderi; Scott B Campbell; Christine E Staatz Journal: Front Pharmacol Date: 2021-04-12 Impact factor: 5.810
Authors: Aswathy M Cheriyan; Adaku C Ume; Cynthia E Francis; Keyona N King; Valerie A Linck; Yun Bai; Hui Cai; Robert S Hoover; Heping P Ma; Jennifer L Gooch; Clintoria R Williams Journal: Am J Physiol Renal Physiol Date: 2021-02-22